PMID- 38091839
OWN - NLM
STAT- MEDLINE
DCOM- 20240110
LR  - 20240110
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 693
DP  - 2024 Jan 22
TI  - The current and emerging Klotho-enhancement strategies.
PG  - 149357
LID - S0006-291X(23)01451-1 [pii]
LID - 10.1016/j.bbrc.2023.149357 [doi]
AB  - Klotho is well known as a gene with antiaging properties. It has membrane and 
      soluble forms, providing a unique system that controls various metabolic 
      processes essential to health and disease. Klotho deficiency has been revealed to 
      be associated with various aging-related disorders. Based on its various known 
      and unknown protective properties, upregulating the Klotho gene may be a possible 
      therapeutic and/or preventive approach in aging-related complications. Some 
      agents, such as hormonal compounds, renin-angiotensin system inhibitors, 
      antioxidants, peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists, 
      statins, vitamin D receptor agonists, antioxidants, anti-inflammatory agents, 
      mammalian target of rapamycin (mTOR) signaling inhibitors, and 
      receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors, can 
      possibly lead to the upregulation and elevation of Klotho levels. Demethylation 
      and deacetylation of the Klotho gene can also be considered other possible 
      Klotho-enhancement methods. Some emerging techniques, such as RNA modifications, 
      gene therapy, gene editing, and exosome therapy, probably have the potential to 
      be applied for increasing Klotho. In the present study, these current and 
      emerging Klotho-enhancement strategies and their underlying mechanisms were 
      comprehensively reviewed, which could highlight some potential avenues for future 
      research.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Poursistany, Haniyeh
AU  - Poursistany H
AD  - Department of Clinical Biochemistry and Laboratory Medicine, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Azar, Solmaz Tabibi
AU  - Azar ST
AD  - Department of Cell and Molecular Biology, School of Biology, College of Science, 
      University of Tehran, Tehran, Iran.
FAU - Azar, Mahsan Tabibi
AU  - Azar MT
AD  - Student Research Committee, Islamic Azad University, Tabriz Branch, Tabriz, Iran.
FAU - Raeisi, Sina
AU  - Raeisi S
AD  - Pediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran. Electronic address: sina_raeisi7007@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20231210
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - EC 3.2.1.31 (Glucuronidase)
RN  - 0 (Antioxidants)
SB  - IM
MH  - *Glucuronidase/genetics/metabolism
MH  - *Signal Transduction
MH  - Antioxidants
MH  - Up-Regulation
OTO - NOTNLM
OT  - Epigenetic modification
OT  - Exosomes
OT  - Gene regulation
OT  - Klotho
OT  - Nonepigenetic modifications
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/12/14 00:42
MHDA- 2024/01/10 06:42
CRDT- 2023/12/13 18:09
PHST- 2023/09/05 00:00 [received]
PHST- 2023/11/24 00:00 [revised]
PHST- 2023/12/04 00:00 [accepted]
PHST- 2024/01/10 06:42 [medline]
PHST- 2023/12/14 00:42 [pubmed]
PHST- 2023/12/13 18:09 [entrez]
AID - S0006-291X(23)01451-1 [pii]
AID - 10.1016/j.bbrc.2023.149357 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2024 Jan 22;693:149357. doi: 
      10.1016/j.bbrc.2023.149357. Epub 2023 Dec 10.